Off-license use of recombinant activated factor VII

被引：58

作者：

Ghorashian, S

Hunt, BJ

机构：

[1] St Thomas Hosp, Guys & St Thomas Trust, Dept Haematol, London SE1 7EH, England

[2] St Thomas Hosp, Guys & St Thomas Trust, Dept Rheumatol, London SE1 7EH, England

来源：

BLOOD REVIEWS | 2004年 / 18卷 / 04期

关键词：

recombinant factor Vlla; bleeding (haemorrhage); coagulation; haemostasis; thrombocytopenia; platelet dysfunction;

D O I：

10.1016/j.blre.2003.12.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recombinant factor VIIa (rFVIIa) has been widely used in the treatment of bleeding episodes in haemophiliac patients with inhibitors. In haemostatic circles it has also been assessed in reversing oral anticoagulant therapy. Over the last few years, it has been used "off-label" in patients with uncontrolled bleeding due to haemostatic abnormalities due to trauma and/or massive blood loss, thrombocytopenia, platelet dysfunction or liver dysfunction. This review examines the proposed mechanism of action of rFVIIa in the context of current concepts of haemostasis and its pharmacological properties. The "off-license" use of rFVIIa is reviewed. The tatter are reported mainly as case reports, case series. There is an overwhelming need for randomized controlled trials to assess rFVIIa's efficacy, dosing and safety in current "off-license" use. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：245 / 259

页数：15

共 101 条

[1]

ABERG M, 1978, ANN SURG, V189, P243

[2]

Abu-Hajir M, 2001, BLOOD, V98, p79B

[3]

AGGARWAL A, 2001, 43 ANN M ORL DEC

[4] Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery [J].